KRRO
Korro BioFOperating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
Peer overview
Direct AATD and delivery-modality comparator: Wave's WVE-006 and Korro's KRRO-111 are subcutaneously delivered, GalNAc-conjugated RNA-editing oligonucleotides. Wave reported patient data from its RestorAATion-2 trial in May 2026, whereas KRRO-111's cited results remain in mice. This is a useful clinical-translation and competitive benchmark, not a transferable valuation multiple. Company source: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-restoraation-2
Grade position vs WVE
Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.

